Your search for supplemental oxygen returned 14 results

Significant reductions seen in RSV-related infections, RSV-related hospitalizations for three monoclonal antibodies versus placebo

The studies evaluated routine clinical practice data from more than 800 hospitals in the US.

Patients with COVID-19 who required low-flow oxygen supplementation were randomly assigned to receive either SNG001 (n=314) or placebo (n=309) once daily for 14 days.

Current evidence indicates that a 6mg dose of dexamethasone daily is effective for improving COVID-19 outcomes among patients receiving supplemental oxygen.

Investigators developed and validated a machine learning tool providing an early indication of disease progression in community-acquired pneumonia.

High-dose inhaled nitric oxide linked to more days free from oxygen supplementation, shorter ICU and hospital length of stay

Lower average oxygen delivery rates seen in association with Asian, Black, Hispanic versus White race, ethnicity

Rates of severe disease low for high-risk patients with mild-to-moderate COVID-19 treated with antispike monoclonal antibodies

Investigators report findings from a secondary analysis of the DARE-19 trial, which compared dapagliflozin with placebo in patients hospitalized with COVID-19.

No significant difference versus placebo observed for hospitalized patients with COVID-19 receiving noninvasive supplemental oxygen